U.S. flag

An official website of the United States government, Department of Justice.

Prescription Drug Monitoring Program: Tennessee State Profile (2021)

NCJ Number
Date Published
13 pages

The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) reports 2020 data and 2021 features of the Tennessee state Prescription Drug Monitoring Program (PDMP).


The anacronym for the Tennessee PDMP is CSMD. It is administered by the Tennessee Department of Health, Tennessee Board of Pharmacy. The email address is provided, along with URLs for the main website and related websites for enrollment, query, and data upload. Contact information is provided for the Director of the CSMD Program and the Clinical Application Coordinator 3. In 2020, the state population was 6,916,897, and there were 38,573 DEA-registered prescribers and 1,607 DEA-registered dispensers. A total of 25 types of PDMP reports are listed as being available. Funding sources are the state general fund, licensing fees, the regulatory board fund, and a BJA grant. The budget for 2021 is not reported. Six staff members perform operational tasks. No staff are reported for technical or analytical/epidemiological work. Dates are listed for key events in the establishment and development of the PDMP. Access information is provided for statutes and rules on PDMP responsibilities and policies. A total of 18 miscellaneous PDMP capabilities and policies are listed. The data retention policy is a minimum of 1 year. No report is provided of available or required training on PDMP features and use. Enrollment with a PDMP account is automatic with prescriber and dispenser license renewal or application. Law enforcement agency access to patient information requires an active investigation or proper need/upon request. Information required for a query is provided. Enrollment in and use of the PDMP are required for prescribers and dispensers. There is a reporting mandate for veterinarians when prescribing drugs for animal treatment. Data monitored or accessible pertain to drugs listed in Schedules II-V. Fatal and non-fatal drug overdoses are monitored, along with pharmaceutical manufacturers/distributors sales.


Date Published: January 1, 2021